Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Sobi) touted a successful conclusion of the Phase IIb COMPARE clinical trial, which showed that SEL-212 performed numerically better than Horizon Therapeutics plc’s Krystexxa (pegloticase) for chronic refractory gout. However, SEL-212 did not measure up to a new emerging standard of care for this patient population, so the drug candidate’s commercial prospects may be reduced.
The COMPARE trial did not meet its primary endpoint, which compared the percentage of patients treated with SEL-212 versus the percentage treated with Krystexxa who achieved and maintained a reduction in serum uric acid of less than 6mg/dL for at least 80% of the time during months 3 and 6 combined
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?